ARTL (Artelo Biosciences) Short-Term Debt: $0.66 Mil (As of Mar. 2026)


ARTL Artelo Biosciences Inc ARTL
31 GF Score
Price $1.10
! 2 Warning Signs
View Full Analysis

What is Artelo Biosciences Short-Term Debt?

Artelo Biosciences ARTL 31 Short-Term Debt is $0.66 Mil as of Mar. 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Artelo Biosciences's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.66 Mil.

Artelo Biosciences's quarterly Short-Term Debt declined from Sep. 2025 ($0.88 Mil) to Dec. 2025 ($0.61 Mil) but then increased from Dec. 2025 ($0.61 Mil) to Mar. 2026 ($0.66 Mil).

Artelo Biosciences's annual Short-Term Debt stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.61 Mil).

Artelo Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Artelo Biosciences Short-Term Debt Related Terms

Artelo Biosciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Artelo Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artelo Biosciences Short-Term Debt Chart

Artelo Biosciences Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.61

Artelo Biosciences Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.79 0.88 0.61 0.66
ARTL
31GF Score
Artelo Biosciences Inc ARTL
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.66 Mil mean?
Artelo Biosciences (ARTL) has a Short-Term Debt of $0.66 Mil as of Mar. 2026.
Is Artelo Biosciences' Short-Term Debt too high?
Artelo Biosciences' current Short-Term Debt is $0.66 Mil. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Short-Term Debt compare to REVB and MTNB?
Artelo Biosciences' Short-Term Debt of $0.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Artelo Biosciences's current Short-Term Debt is $0.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Short-Term Debt of $0.66 Mil. The current Short-Term Debt is $0.66 Mil. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Short-Term Debt is $0.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artelo Biosciences Business Description

Address 505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score

Get the complete analysis for ARTL

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.10
Price